Drugs / SPX-303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06259552 | Mar 2024 → Sep 2027 expected | head and neck squamous cell carcinoma, renal cell carcinoma | SparX Biotech(Jiangsu) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPX-303 | “A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors” NCT06259552 ↗ |
| Known as | SPX- 303 Injection | “SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody” NCT06259552 ↗ |
| Route | Intravenous | “SPX-303 will be administered intravenously (IV)” NCT06259552 ↗ |
| Target | LILRB2 | “a bispecific anti-LILRB2 / anti-PD-L1 Antibody” NCT06259552 ↗ |